XTX Topco Ltd Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)

XTX Topco Ltd acquired a new position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 83,437 shares of the company’s stock, valued at approximately $185,000. XTX Topco Ltd owned approximately 0.19% of Cardiff Oncology at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Callan Capital LLC increased its holdings in Cardiff Oncology by 37.2% in the 1st quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock worth $228,000 after purchasing an additional 11,600 shares in the last quarter. Blair William & Co. IL raised its holdings in Cardiff Oncology by 32.4% in the 1st quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock valued at $919,000 after buying an additional 42,180 shares during the last quarter. Vanguard Group Inc. boosted its position in Cardiff Oncology by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock worth $10,260,000 after buying an additional 9,468 shares during the period. Assenagon Asset Management S.A. grew its holdings in Cardiff Oncology by 380.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after acquiring an additional 962,940 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Cardiff Oncology in the 2nd quarter valued at approximately $256,000. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

Cardiff Oncology stock opened at $2.67 on Tuesday. The firm has a market cap of $124.29 million, a price-to-earnings ratio of -2.97 and a beta of 1.95. Cardiff Oncology, Inc. has a 52-week low of $0.94 and a 52-week high of $6.42. The firm has a 50 day moving average price of $2.37 and a two-hundred day moving average price of $3.22.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.12 million. During the same period last year, the business posted ($0.25) earnings per share. As a group, equities research analysts predict that Cardiff Oncology, Inc. will post -1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on Cardiff Oncology in a report on Friday, September 6th. They set a “buy” rating and a $8.00 target price on the stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.